Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate (cORR) of 41.3%, median duration of response (DOR) of 12.9 months, and median progression-free survival  Continue Reading

VANCOUVER, British Columbia , June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Jefferies Global  Continue Reading

VANCOUVER, British Columbia , May 18, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the departure of Neil Klompas , President and Chief Operating Officer. Mr.  Continue Reading

Confirmed prior guidance on 2023 operating cash burn of between $90 and $120 million and cash runway through at least 2026, and potentially beyond Net quarterly loss decreased by 66% to $24.4 million as compared to first quarter in 2022 Presented 11 posters at the American Association for Cancer  Continue Reading

VANCOUVER, British Columbia , May 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Bank of America  Continue Reading

● ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft (PDX)   models with favorable pharmacokinetic and safety profiles ● ZW171 induced potent preferential killing of cancer cells and potential to mitigate risk of on-target off-tumor toxicity, peripheral T cell  Continue Reading

VANCOUVER, British Columbia --(BUSINESS WIRE)--Apr. 17, 2023-- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2023 financial results after market close on May 8,  Continue Reading

VANCOUVER, British Columbia --(BUSINESS WIRE)--Apr. 10, 2023-- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023 . Mr.  Continue Reading

VANCOUVER, British Columbia --(BUSINESS WIRE)--Apr. 3, 2023-- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: 2023 Bloom Burton &  Continue Reading

Eleven abstracts accepted for poster presentation highlight company’s differentiated antibody drug conjugate, multispecific antibody, and clinical product candidates Management will host a conference call on April 18 th at 6:30 pm Eastern Standard Time (EST) VANCOUVER, British Columbia --(BUSINESS  Continue Reading